Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Endocrinology · Vasoactive Intestinal Peptide–Secreting Tumor (VIPoma)

Life After Treatment: Monitoring and Long-Term Care

At a Glance

After VIPoma treatment, individualized long-term follow-up matters because recurrence can occur even after clear margins and, rarely, 15 to 22 years later. Monitoring may include VIP and electrolyte tests, CT or MRI scans, and broader surveillance for MEN1.

The transition from active treatment to surveillance is a significant milestone, but because VIPoma is rare and its behavior can be unpredictable, your care team will recommend individualized long-term monitoring [1]. The goal of this phase is to detect any potential recurrence as early as possible and to manage the long-term health of your endocrine system [2].

The Risk of Late Recurrence

Even if your surgery was considered “curative” and your margins were clear, VIPoma has a risk of returning.

  • Recurrence Rates: In some retrospective reviews, the recurrence rate for localized VIPoma is approximately 40%, though risk is strongly stage-, grade-, size-, and node-dependent [3].
  • The “Long Tail”: Unlike many common cancers, VIPomas have been documented to recur as late as 15 to 22 years after the original surgery in rare cases [4][5].
  • Grading and Risk: Tumors with a higher Ki-67 index (a measure of cell division) or those that had already spread to lymph nodes at the time of surgery generally have a higher risk of coming back [6][7].

Your Monitoring Strategy: Blood and Bio-markers

The most reliable early warning sign of a VIPoma returning is often your own body’s reaction, paired with lab results.

  • Tracking Symptoms and VIP: While a return of watery diarrhea can sometimes track with a rise in VIP levels, recurrence can also be asymptomatic, and diarrhea has many other causes [8]. Do not wait for a scheduled imaging test if you experience new high-volume diarrhea—contact your team promptly.
  • Serial Lab Work: Your biochemical follow-up is individualized based on whether VIP was elevated and informative at your baseline [9]. Your team will also check your potassium, bicarbonate, and kidney function (creatinine) to ensure your electrolytes remain balanced [8][10].

Imaging: Choosing the Right Scans

To check for physical tumor growth, your doctor will order periodic scans, spaced according to your grade and stage.

  • CT and MRI: Contrast-enhanced CT scans and MRIs are standard for follow-up [11]. MRI is highly sensitive at finding liver metastases and does not use radiation, while multiphasic CT gives excellent anatomic detail [11].
  • A Note on DOTATATE PET/CT: While somatostatin-receptor PET was likely essential for your initial staging, it is not always used at every routine surveillance visit [11]. It remains very useful for suspected recurrence, treatment planning, or clarifying equivocal findings on a CT or MRI [12][13]. MRI, CT, and PET have complementary roles.

Special Considerations for MEN1

If your VIPoma is associated with Multiple Endocrine Neoplasia type 1 (MEN1), your monitoring will be coordinated through an endocrinology team [14].

  • Broad Surveillance: Surveillance is broader than just checking VIP; it involves tailored biochemical screening and imaging for parathyroid, pituitary, and other endocrine tumors depending on your symptoms and hormone results [15][14].
  • Genetic Counseling: Cascade genetic testing of first-degree relatives (parents, siblings, children) is recommended when a germline MEN1 pathogenic variant or clinical MEN1 diagnosis is established [16][17].

Living with “Scanxiety”

Living with a rare tumor that requires lifelong monitoring can create a heavy psychological burden often called “scanxiety”—the intense anxiety felt before and during follow-up scans. It is helpful to remember that many treatments (including repeat surgery, PRRT, or targeted pills) can successfully manage the disease for many years if it returns [1][18]. Seeking out a neuroendocrine tumor (NET) support group, speaking with an oncology social worker, or finding reputable patient organizations can provide practical support and connection with others who understand.

Common questions in this guide

How often are follow-up visits needed after VIPoma treatment?
There is no single schedule for everyone; your team will base visits, blood tests, and scans on your tumor’s stage, grade, size, lymph-node involvement, and whether VIP was useful at baseline. Because VIPoma can recur late, follow-up may continue for many years even after clear surgical margins.
Can a VIPoma return after surgery if the margins were clear?
Yes. VIPoma can recur even after surgery described as curative and, in rare cases, has returned 15 to 22 years later; a higher Ki-67 index, which reflects faster cell division, or lymph-node involvement is linked with greater recurrence risk.
What blood tests help monitor VIPoma after treatment?
Your team may measure VIP if it was elevated and informative when you were first diagnosed, along with potassium, bicarbonate, and creatinine to check electrolyte balance and kidney function. New high-volume watery diarrhea should prompt a call rather than waiting for the next test, although diarrhea can have causes unrelated to recurrence.
Which scans are used to look for VIPoma recurrence?
Contrast-enhanced CT and MRI are common follow-up scans; MRI is particularly useful for detecting liver spread without radiation, while multiphasic CT provides detailed anatomy. DOTATATE PET/CT may be used when recurrence is suspected, a CT or MRI is unclear, or treatment is being planned, rather than at every routine visit.
How does MEN1 change follow-up for someone with VIPoma?
MEN1 usually means broader follow-up coordinated by endocrinology, including tailored blood tests and imaging for the parathyroid, pituitary, and other endocrine tumors. If a clinical MEN1 diagnosis or inherited MEN1 variant is confirmed, parents, siblings, and children may be referred for genetic counseling and testing.
How can I manage anxiety before VIPoma follow-up scans?
Scan-related anxiety is common during long-term monitoring. An oncology social worker, neuroendocrine tumor support group, reputable patient organization, counselor, or trusted family member may provide practical and emotional support.

Get notified when new evidence is published on pancreatic vasoactive intestinal peptide producing tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

    Bartsch DK, Mais L, de Mestier L, et al.

    Journal of neuroendocrinology 2026; (38(7)):e70219 doi:10.1111/jne.70219.

    PMID: 42338092
  2. 2

    European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.

    Hofland J, Falconi M, Christ E, et al.

    Journal of neuroendocrinology 2023; (35(8)):e13318 doi:10.1111/jne.13318.

    PMID: 37578384
  3. 3

    Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.

    Schizas D, Mastoraki A, Bagias G, et al.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2019; (24(2)):415-423.

    PMID: 31127985
  4. 4

    A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection.

    Sakurai M, Wakabayashi T, Kondo Y, et al.

    Endocrine journal 2023; (70(6)):573-579 doi:10.1507/endocrj.EJ22-0578.

    PMID: 36889692
  5. 5

    Recurrent primary hepatic VIPoma treated with a combination of surgical resection and loco-regional therapy.

    Dahmani W, Nasr S, Maalel K, et al.

    Future science OA 2023; (9(1)):FSO836 doi:10.2144/fsoa-2022-0046.

    PMID: 37006228
  6. 6

    The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center Analysis.

    Podrascanin V, Ammann M, Gudmundsdottir H, et al.

    Annals of surgical oncology 2026; (33(4)):3425-3434 doi:10.1245/s10434-025-18887-1.

    PMID: 41419712
  7. 7

    Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.

    Andreasi V, Ricci C, Partelli S, et al.

    Journal of endocrinological investigation 2022; (45(4)):705-718 doi:10.1007/s40618-021-01705-2.

    PMID: 34773595
  8. 8

    Prevalence of Diagnostic Methods and Treatment Modalities in Vipoma Patients: A Rare Cause of Hormone-Mediated Diarrhea.

    Amiri FS

    Indian journal of endocrinology and metabolism 2019; (23(3)):318-325 doi:10.4103/ijem.IJEM_105_19.

    PMID: 31641634
  9. 9

    Pancreatic Vasoactive Intestinal Peptide-Producing Tumor as a Rare Cause of Acute Diarrhea and Severe Hypokalemia.

    Giampatzis V, Kotsiari C, Bostantzis P, et al.

    Journal of medical cases 2023; (14(9-10)):307-316 doi:10.14740/jmc4141.

    PMID: 37868325
  10. 10

    Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma.

    Negro A, Verzicco I, Tedeschi S, et al.

    Frontiers in endocrinology 2021; (12()):652045 doi:10.3389/fendo.2021.652045.

    PMID: 33815297
  11. 11

    ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.

    , Yacoub JH, Yano M, et al.

    Journal of the American College of Radiology : JACR 2026; (23(7)):1445-1461 doi:10.1016/j.jacr.2026.02.012.

    PMID: 41823937
  12. 12

    Imaging surveillance in multiple endocrine neoplasia type 1: Ten years of experience with somatostatin receptor positron emission tomography.

    Said M, Krogh J, Feldt-Rasmussen U, et al.

    Journal of neuroendocrinology 2023; (35(8)):e13322 doi:10.1111/jne.13322.

    PMID: 37564005
  13. 13

    Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.

    Ambulkar KS, Shah R, Lila A, et al.

    Nuklearmedizin. Nuclear medicine 2025; (64(5)):301-307 doi:10.1055/a-2694-8248.

    PMID: 41005352
  14. 14

    Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.

    Brandi ML, Pieterman CRC, English KA, et al.

    The lancet. Diabetes & endocrinology 2025; (13(8)):699-721 doi:10.1016/S2213-8587(25)00119-6.

    PMID: 40523372
  15. 15

    The Importance of Periodical Screening for Primary Hyperparathyroidism in a Pituitary Tumor Cohort in Searching Patients With MEN1 and Its Genetic Profile.

    Damianse SSP, Nascimento GC, Rocha VCC, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(5)):509-514 doi:10.1016/j.eprac.2022.02.010.

    PMID: 35247589
  16. 16

    Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group.

    van Leeuwaarde RS, van Nesselrooij BP, Hermus AR, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(3)):1159-65 doi:10.1210/jc.2015-3766.

    PMID: 26751192
  17. 17

    Genetic test in multiple endocrine neoplasia type 1 syndrome: An evolving story.

    Marini F, Giusti F, Brandi ML

    World journal of experimental medicine 2015; (5(2)):124-9 doi:10.5493/wjem.v5.i2.124.

    PMID: 25992327
  18. 18

    Efficacy of treatments for VIPoma: A GTE multicentric series.

    Brugel M, Walter T, Goichot B, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021; (21(8)):1531-1539 doi:10.1016/j.pan.2021.08.001.

    PMID: 34404601

This page is for informational purposes only and does not constitute medical advice. Your endocrinology and oncology teams should set your personalized VIPoma monitoring schedule and interpret your results.

Guide contents pancreatic vasoactive intestinal peptide producing tumor
Research & Literature
05 Standard Treatments for the Tumor